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Abstract 
Background 
Nuclear import of protein kinase D1 (PKD1) is an important event in the transcriptional 
regulation of cardiac gene reprogramming leading to the hypertrophic growth response, 
however, little is known about the molecular events that govern this event. We have 
identified a novel complex between PKD1 and a heat shock protein (Hsp), Hsp20, which has 
been implicated as cardioprotective. This study aims to characterize the role of the complex 
in PKD1-mediated myocardial regulatory mechanisms that depend on PKD1 nuclear 
translocation. 
Results 
In mapping the Hsp20 binding sites on PKD1 within its catalytic unit using peptide array 
analysis, we were able to develop a cell-permeable peptide that disrupts the Hsp20-PKD1 
complex. We use this peptide to show that formation of the Hsp20-PKD1 complex is 
essential for PKD1 nuclear translocation, signaling mechanisms leading to hypertrophy, 
activation of the fetal gene programme and pathological cardiac remodeling leading to 
cardiac fibrosis. 
Conclusions 
These results identify a new signaling complex that is pivotal to pathological remodelling of 
the heart that could be targeted therapeutically. 
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Introduction 
Cardiac myocytes respond to pathological stress via activation of the fetal gene programme 
(reviewed in [1]). Essential to this process, is the activation of cardiac protein kinase D 
(PKD). PKD1 is a ubiquitously expressed serine/threonine kinase and is the most 
characterised member of a kinase family within the CaMK group (comprising PKD1, PKD2, 
and PKD3) of kinases [2]. In the adult heart, PKD1 is activated in response to chronic 
adrenergic signalling, hypertension and pressure overload. Phosphorylation and hence 
activation of PKD1 occurs initially via binding to diacylglycerol [3] at its cystein-rich domain 
with kinase activation/translocation being triggered by PKC-phosphorylation and the release 
of pleckstrin homology (PH)-mediated PKD1 inhibition [4]. Upon cell stimulation, PKD 
isoforms translocate from the cytosol to DAG-containing microenvironments at the plasma 
membrane and then back to the cytosol and into the nucleus [5]. PKD has been implicated in 
a variety of cellular responses including cell proliferation, inflammation, cardiac contractility 
and hypertrophy [2]. In the heart, PKD1 has been shown to regulate myofilament function 
and Ca
2+
 sensitivity by phosphorylating cardiac troponin I [6,7]. PKD1 also regulates cardiac 
myocyte hypertrophy by translocating into the nucleus and directly phosphorylating class II 
histone deacetylase 5 (HDAC5) [8]. HDACs deacetylate histones resulting in transcriptional 
repression. HDAC phosphorylation, for example by PKD1 and CaMKII [9], creates docking 
sites for 14-3-3 chaperone proteins that escorts them from the nucleus to the cytoplasm, thus 
relieving downstream transcription factors (such as myocyte enhancer factor-2 (MEF2)), of 
their repression [10,11]. However, little is known about the molecular events that govern 
PKD1 nuclear translocation. 
In a proteomics screen to discover novel partners for the chaperone heat shock protein 20 
(Hsp20), we found PKD1 to be a robust Hsp20-binding protein. Hsp20 (reviewed in [12]) 
displays cardioprotective actions including anti-ischaemic, anti-apoptotic and anti-
hypertrophic effects. At basal level, HSP20 is primarily found in the cytosol but a 
subpopulation may translocate into the nuclear compartment in response to stress signals 
[13]. 
In this manuscript, we verify the interaction between Hsp20 and PKD1 and use novel peptide 
disruptors to show firstly, that formation of the Hsp20-PKD1 complex is required for 
hypertrophic signaling, secondly, that Hsp20 facilitates the nucleo-cytoplasmic shuttling of 
PKD1 and thirdly, that the Hsp20-PKD1 interaction promotes stress related left ventricular 
(LV) dysfunction and cardiac fibrosis. 
Results and discussion 
Hsp20 and PKD1 form a complex in cardiac myocytes 
The protective functions of Hsp20 in a cardiac setting have received much attention and in an 
attempt to elucidate the molecular mechanisms involved, we endeavored to characterise 
putative interactors of Hsp20 using high-density ProtoArray Human Protein Microarray 
(Invitrogen, UK) analysis. Using this method, a previously unknown Hsp20-binder was 
identified as PKD1 (Figure 1A). The interaction was verified by pull-down analysis of 
recombinant proteins (Figure 1B) and immunoprecipitation of exogenously (Figure 1C) and 
endogenously (Figure 1D) expressed cardiac myocyte proteins. Co-localisation 
immunostaining (Figure 1F) demonstrated positive correlation in HEK293 cells 
overexpressing Hsp20 and PKD1 (Pearson’s 0.62 ± 0.03, Manders’ 0.81 ± 0.02, M1 0.96 ± 
0.01, M2 0.95 ± 0.01) and in myocytes expressing endogenous Hsp20 and PKD1 (Pearson’s 
0.81 ± 0.02, Manders’ 0.88 ± 0.01, M1 0.86 ± 0.03, M2 0.93 ± 0.01). This data suggests that 
Hsp20 and PKD1 locate to the same region of cells. Peptide array technology was also 
utilized, where the sequence of PKD1 was spotted in 25mer peptides, each shifted by five 
amino acids [14]. As shown in Figure 1E, Hsp20 interacted directly with PKD1, and the 
interaction site was mapped to a 25mer sequence spanning residues 606 to 630 within the 
PKD1 catalytic unit. Subsequent alanine scanning peptide array, whereby every amino acid 
was replaced sequentially with alanine, pinpointed the residues on PKD1 that are essential for 
interaction as R607, D608, V609, I611, I613, D615, E624 (Figure 1E lowest panel). 
Figure 1 PKD1 and Hsp20 form a signaling complex in cardiac myocytes. A. ProtoArray 
Human Protein Microarray screen identified PKD1 as an interacting partner for Hsp20 (top 
panel, compared to control, bottom panel). B. In vitro pull-down assay showed that 
recombinant His-Hsp20, but not control His-tag, co-purifies with PKD1. C. Overexpressed 
Hsp20-V5 and GFP-PKD1 co-immunoprecipitate when expressed in HEK293 cells. D. 
Endogenous Hsp20 and PKD1 from cardiac myocyte lysate co-immunoprecipitate. Mock IP 
represents respective IgG only. Data representative of n = 3 independent experiments.E. 
Peptide array analysis identifies Hsp20 binding site within the catalytic domain of PKD1 
(G
606
-E
630
). F. Overexpressed Hsp20-V5 and GFP-PKD1 co-localise in HEK293 cells and 
endogenous Hsp20 and PKD1 co-localise in cardiac myocytes. Pearson’s coefficient for 
Hsp20 and PKD1 is shown along with Manders’ coefficients (M1 and M2), which represent 
the fraction of the Hsp20 red overlapping with PKD1 green and the fraction of PKD1 green 
overlapping with the Hsp20 red, respectively. The results are shown as means ± SEM of 
several images where at least 10 individual cells were analysed for each coefficient. 
The Hsp20-PKD1 complex is required for hypertrophic 
signaling 
As both PKD1 and Hsp20 are strongly implicated in hypertrophic signaling [11,13,15], we 
decided to probe the functionality of the complex by using cell-permeable peptides, designed 
using the information gleaned from peptide array analysis (Figure 1E), to disrupt the Hsp20-
PKD1 interaction. Previous work from our group has shown that cell-permeable analogues of 
25mer peptides identified in this manner, often can be used to disrupt signalling complexes, 
thereby effecting specific cardiovascular-specific functional outputs such as phosphorylation 
of the β2-adrenergic receptor by PKA [16], recruitment of EPAC to the β 2-adrenergic 
receptor [17], permeability of the vascular epithelium [18] and tubule formation by human 
arterial endothelial cells [19]. Indeed, we have already used this approach successfully to 
disrupt another Hsp20 binding partner, PDE4D5, in order to induce cardioprotection [15]. 
Gratifyingly, a disruptor peptide comprising of PKD1 residues 606 to 630 (DIS), but not a 
control peptide (CTR) with three of the seven key residues replaced by alanine 
(GAAVAIKIIAKLRFPTKQESQLRNE), ablated co-immunopreciptation of endogenous 
Hsp20 and PKD1 from neonatal cardiac myocyte lysates (Figure 2A). As we could 
successfully disrupt the Hsp20-PKD1 complex with disruptor peptide (Figure 2A), we were 
interested to see if it would be able to attenuate the hypertrophic response induced by chronic 
β-agonist (isoprenaline; ISO) stimulation of neonatal cardiac myocytes. To this end, we 
utilised 3 different assay methods to measure the effectiveness of the peptide to confer 
protection against β-adrenergic receptor-triggered hypertrophic signalling. Firstly, we 
employed a novel approach utilizing xCELLigence technology, which we have previously 
developed [15] to measure the size of cardiac myocytes (Figure 2B and C). Secondly, we 
measured the relative protein/DNA ratio of cells (Figure 2D) and thirdly, in order to 
investigate whether the peptide affected increased fetal gene expression that characterises the 
hypertrophic response, we determined the mRNA levels of 3 hypertrophy marker genes atrial 
naturietic peptide (ANP), brain naturietic peptide (BNP) and β-myosin heavy chain (β-MHC) 
(Figure 2E). All three techniques suggested that the disruptor peptide (but not control 
peptide) could attenuate the hypertrophic response. Note that differences seen in BNP 
between ISO and ISO plus control peptide are not significant (p = 0.46) Cell size, measured 
in real-time by cell index (CI; Figure 2B and C) and protein/DNA ratio (Figure 2D) of cells 
increased following chronic ISO treatment and were significantly reduced by pre-treatment 
with disruptor peptide but not with control peptide. The Hsp20-PKD1 disruptor peptide also 
significantly reduced the upregulation of fetal gene expression (Figure 2E) triggered by 
chronic β-agonist stimulation. Another key characteristic of hypertrophy is the reorganization 
of actin filaments [20] and we were able to observe the expected formation of β-adrenergic–
stimulated stress fibers when compared with untreated cells (Figure 2F). Interestingly, the 
actin cytoskeletal rearrangement stimulated by hypertrophy induction was visibly reduced in 
cells pre-treated with disruptor peptide, but not control peptide, (Figure 2F) suggesting that 
the Hsp20-PKD1 association is also likely to have the capacity to regulate the integrity of 
cellular actin filaments. 
Figure 2 Disruption of the Hsp20-PKD1 complex attenuates hypertrophic signaling in 
neonatal cardiac myocytes. A. A cell permeable disruptor peptide (DIS), but not scrambled 
control (CTR), ablates interaction of PKD1 and Hsp20 in cardiac myocytes. B. and C. The 
Hsp20-PKD1 disruptor peptide reduces cardiac myocyte cell size following chronic β-
adrenergic (isoprenaline; ISO) stimulation. D. The Hsp20-PKD1 disruptor peptide reduces 
relative protein/DNA ratio of cells following chronic β-adrenergic stimulation (n = 9). E. The 
Hsp20-PKD1 disruptor peptide reduces the expression of hypertrophic markers atrial 
natruiretic peptide (ANP), brain natruiretic peptide (BNP) and β-myosin heavy chain (β-
MHC) following chronic β-adrenergic stimulation (n = 7). F. The Hsp20-PKD1 disruptor 
peptide reduces actin cytoskeletal rearrangement following chronic β-adrenergic stimulation. 
Data representative of n = 3 independent experiments. 
Hsp20 acts as a nuclear import chaperone for PKD1 
In normal functioning cardiac myocytes, the majority of PKD1 localises to the cytosol, while 
a subpopulation is found in various organelles, such as the nucleus, plasma membrane, 
mitochondria and trans Golgi network [21]. PKD1 is bound by DAG at its cystein-rich 
domain and kinase activation/translocation is triggered by PKC-phosphorylation and the 
release of PH-mediated PKD1 inhibition [5]. This chain of molecular events promotes PKD1 
activation, and it has been established that PKD1 undergoes nuclear shuttling to initiate gene 
transcription following chronic β-adrenergic -agonist stimulation [8]. However, little is 
known about the molecular events that underpin PKD1 nuclear translocation. A-kinase 
anchoring protein (AKAP-Lbc), a protein that is known to bind PKD1 [22] and Hsp20 [23], 
can coordinate and activate movement of signaling proteins that initiate MEF2-mediated 
transcription, however, the AKAP does not directly facilitate nuclear entry of PKD1 as the 
scaffold does not change localization following agonist stimulation. To investigate a possible 
role for Hsp20 in the nuclear influx of PKD1, we used a novel in situ proximity ligation assay 
(PLA) to allow high resolution of the distribution of the Hsp20-PKD1 complex (Figure 3). 
Under basal, unstimulated conditions, diffuse cytoplasmic staining of Hsp20-PKD1 
complexes were observed suggesting that the Hsp20-PKD1 complex was excluded from the 
nucleus (Figure 3A). In contrast, Hsp20-PKD1 complexes were significantly enriched, with 
increased localization to the nuclei of ISO-treated cardiac myocytes (Figure 3A and B). A 
similar distribution pattern was also observed in cells treated with control peptide + ISO. 
However, treatment of the cells with disruptor peptide triggered a significant change in the 
intracellular localisation of Hsp20-PKD1 complexes. When the interaction between the two 
proteins was perturbed, significantly less Hsp20-PKD1 complex was visible globally and 
complexes that were observed showed little nuclear localization (Figure 3A and B). To 
support findings from the PLA assays and evaluate the degree of Hsp20-PKD1 complex 
distribution, we resorted to conventional cell fractionation (Figure 3C). In agreement with 
data from PLA experiments, ISO treatment triggered translocation of both PKD1 and Hsp20 
to the nucleus that could be attenuated with the disruptor peptide but not with control (Figure 
3D and E). PKD1 nuclear translocation during hypertrophic stimulus has been characterised 
previously by others [22,24,25] however, this is the first indication that the said nuclear 
import of PKD1 is directly mediated by another protein (in this case Hsp20). 
Figure 3 Hsp20 may act as a nuclear chaperone for PKD1. A and B. A novel proximity 
ligation assay was used to visualize and quantify PKD1 nuclear entry in neonatal cardiac 
myocytes. Images are shown as maximum projections of z-stacks of confocal images. PLA 
signals indicating Hsp20-PKD1 complex formation were quantified using the analyse 
particles plugin of ImageJ software. For all experiments, quantifications were performed 
from at least 12 images and expressed as mean number of signals per cell.C, D and E. Cell 
fractionation techniques were used to visualize and quantify the cellular distribution profile of 
PKD1 and Hsp20 from cardiac myocytes. The disruptor peptide (PKD DIS) prevented ISO-
induced nuclear translocation of Hsp20-PKD1 complexes, compared to control peptide (CTR 
PKD). Data representative of n = 3 independent experiments. 
The Hsp20-PKD1 complex directs cardiac hypertrophy 
and cardiac fibrosis in vivo 
Studies utilizing mice that have a cardiac-specific deletion of PKD1 [26] showed that PKD1 
acts as a key element of the stress-stimulated signaling pathway involved in pathological 
cardiac remodeling. One crucial component of cardiac remodeling, contributing to 
compromised diastolic function, is cardiac fibrosis. Interestingly, these mice showed not only 
diminished cardiac myocyte hypertrophy but also significantly reduced cardiac fibrosis. This 
added to previous indirect evidence suggesting that PKD1 has a role in controlling cardiac 
fibrosis [27,28]. 
To this end, we used a minimally invasive transverse aortic banding (MTAB) model of 
pressure overload induced cardiac hypertrophy [29] and compared them to sham-operated 
mice following treatment with the Hsp20-PKD1 disruptor and control peptides. Treatment 
with disruptor peptide, but not control, prevented MTAB-induced decreases in left ventricular 
contractility (Figure 4; %fractional shortening: 44.0 ± 1.0% cf. 29.5 ± 4.0%, p < 0.0001, 
MTAB+DIS PKD and MTAB+CTR PKD, respectively). Analysis of picrosirius red stained 
heart sections from mice treated with control peptide showed significantly increased collagen 
deposition (fibrosis) in MTAB mice compared with sham-operated mice (Figure 5; 16.3 ± 
2.8% (MTAB+CTR PKD) cf. 8.1 ± 0.5% (sham+CTR PKD), p < 0.01). In contrast, hearts 
from MTAB mice treated with the Hsp20-PKD1 disruptor showed significantly reduced 
fibrosis when compared with MTAB mice treated with control peptide (Figure 5; 5.2 ± 1.5% 
(MTAB+PKD DIS) cf. 16.3 ± 2.8% (MTAB control) p < 0.001). This data suggests that 
interdiction of the Hsp20-PKD1 complex is protective against accumulation of fibrillar 
collagen and development of the cardiac fibrosis that accompanies hypertrophic remodelling 
following pressure overload. 
Figure 4 Preserved cardiac function following Hsp20-PKD1 disruption. Mice undergoing 
sham or MTAB surgery were treated with 10 mg/kg PKD-disruptor (PKD DIS) or a 
scrambled control (CTR PKD) peptide twice weekly for 4 weeks. A. Representative LV 
echocardiography M-mode traces; AW, anterior wall; PW, posterior; EDD, end diastolic 
diameter; ESD, end systolic diameter. B. Histogram of average ± S.E.M fractional shortening 
data, n ≥ 5 mice, *p < 0.05, ***p < 0.001, one-way ANOVA tests followed by post-hoc 
Tukey’s test. 
Figure 5 Cardiac fibrosis is attenuated by disruption of Hsp20-PKD1 interaction. A. 
Picrosirius red staining of sham and MTAB hearts following treatment of mice with 10 
mg/kg PKD-disruptor (PKD DIS) or scrambled control (CTR PKD) peptide twice weekly for 
4 weeks. B. Histogram values represent stained area expressed as a percentage of the total 
area of interest. Data represents mean ± S.E.M., n ≥ 3 mice, **p <0.01, ***p < 0.001, ns p > 
0.05, one-way ANOVA tests followed by post hoc Tukey’s tests. 
Conclusions 
In summary, we have discovered a novel protein complex (Hsp20-PKD1) that appears to 
orchestrate hypertrophy signalling pathways involved in the induction of fetal gene program, 
pathological cardiac growth and cardiac remodeling. As disruption of the complex 
significantly retards these processes, we propose, the Hsp20-PKD1 signalling axis as a 
promising therapeutic target to hinder the hypertrophic phenotype. Development of Hsp20-
PKD1 disruptors to prevent PKD1 nuclear translocation represents a novel route for the 
development of anti-hypertrophic and anti-fibrotic agents. 
Methods 
Peptides 
Hsp20-PKD1disruptor (GRDVAIKIIDKLRFPTKQESQLRNE) and control peptide 
(GAAVAIKIIAKLRFPTKQESQLRNE) were synthesised by GenScript and included an N-
terminal stearoyl group (CH3(CH2)16COOH) making them cell permeable. For cell studies 
peptides were dissolved in DMSO to a stock concentration of 10 mM and used at a final 
concentration of 10 μM, and for in vivo studies were dissolved in sterile saline to 1 mg/ml. 
Antibodies 
Anti-His (H1029), anti-V5 antibodies (V8137) and anti-Actinin (A7811) were from Sigma. 
Anti-HSP20 antibody was from Millipore (07–490). Anti-GFP (ab290), anti-phospho-HSP20 
(ab58522), anti-HSP90 (ab13495) and anti-GM130 (ab52649) antibodies were from Abcam. 
Anti-PKD1 (sc-639) and anti-Lamin A/C (sc-56140) antibodies were from Santa Cruz. Anti-
PKD1 (H00005587-A01) for immunostaining was from Abnova. 
Cell culture, transfection, Western blotting and immunoprecipitation 
Neonatal rat cardiac myocytes were cultured as described before [30]. For hypertrophy 
induction, cells were cultured in serum-free medium for 48 h prior to stimulation by 10 μM of 
ISO for 24 h and where appropriate, cardiac myocytes were pretreated with compounds. 
DNA plasmid constructs used for transfection included V5-HSP20 in pDEST vector and 
GFP-PKD1 in pEF-BOS vector. HEK 293 cells were transiently transfected with both 
plasmid DNA using Polyfect Transfection Reagent (Qiagen) following the manufacturer’s 
instruction. Cellular lysates were prepared in lysis buffer [25 mM Hepes, 2.5 mM EDTA, 50 
mM NaC1, 50 mM NaF, 30 mM sodium pyrophosphate, 10% (v/v) glycerol, 1% (v/v) Triton 
X-100, pH 7.5, containing Complete™ EDTA-free protease inhibitor cocktail tablets 
(Roche)] after specified treatments. Protein concentration of lysates was determined using the 
Bradford assay and all samples were equalised for protein concentration. Proteins were 
separated by SDS/PAGE (4–12% Bis-Tris gels) and transferred onto nitrocellulose 
membranes for Western blotting. For immunoprecipitation, HSP20 or PKD1 and V5 or GFP 
antibodies were used to immunoprecipitate endogenous, and over-expressed PKD1 and 
HSP20, respectively. The resulting immunocomplexes were captured using Protein A beads 
(Invitrogen) at 4°C overnight with shaking. The immunocomplexes were then collected by 
centrifugation at 10 000 × g for 3 min and washed three times with 3T3 lysis buffer. Bound 
proteins were then eluted in SDS-PAGE sample buffer and subjected to SDS-PAGE and 
immunoblotting. Negative controls using isotype-matched IgG (Jackson ImmunoResearch 
Laboratories, Inc.) from the same species as the antibodies were included to screen for non-
specific binding. Immunoreactive proteins were detected using horseradish peroxidase-
conjugated goat anti-rabbit or anti-mouse secondary antibody (1:5000, Sigma-Aldrich) and 
visualized by enhanced chemiluminescence detection (Pierce). Quantification of the band 
intensity was accomplished by densitometry using Quantity One 1-D software (Bio-Rad). 
ProtoArray 
To prepare the probe for ProtoArray analysis, Ultimate™ ORF clone IOH57317 (Invitrogen), 
containing the open reading frame (ORF) of HSP20 in pENTR221 vector, was used to 
generate N-terminal His-fusion protein by Gateway cloning technology into pDEST-17 
vector (Invitrogen). The His-tagged HSP20 protein was expressed in E.coli and purified by 
Ni-NTA Superflow resin (Qiagen). Coomassie Blue staining and Western blot with mouse 
monoclonal anti-His antibody (Sigma) and rabbit polyclonal anti-HSP20 antibody (Upstate-
Millipore) verified the purity and specificity of the probes. Briefly, the array was incubated in 
blocking buffer (1×PBS, 1% BSA and 0.1% Tween 20) for 1 h at 4°C with gentle shaking to 
block non-specific binding. The array was then probed with 10 μM (200 μg/ml) of His-
HSP20 protein in probing buffer (1×PBS, 5 mM MgCl2, 0.5 mM dithiothreitol (DTT), 0.05% 
Triton X-100, 5% glycerol, 1% BSA) for 1.5 h at 4°C. After washing, the array was 
incubated at 4°C with mouse monoclonal anti-His antibody (Sigma) and Alexa Fluor 647 
goat anti-mouse IgG (H + L) (Molecular Probes, Invitrogen) diluted 1:2000 in probing buffer 
for 45 min and 30 min, respectively. After washing and drying, the array was scanned by 
ScanArray Express Microarray Scanner (Packard Bioscience Biochip Technology, 
PerkinElmer) at a wavelength of 633 nm. The results were analysed using BlueFuse for 
Microarrays software (BlueGnome, Cambridge), following acquisition of the ProtoArray Lot 
Specific information. The Confidence Flags were used to indicate the degree of confidence 
showing potential interactions. A control array was also included in parallel to determine 
probe-specific interactions and exclude any non-specific interactions. 
In vitro pull-down assay 
Equal molar concentrations of purified recombinant His (negative control) or His-HSP20 and 
PKD1 (Abcam) were mixed in 3T3 lysis buffer and incubated end-on-end with gentle 
agitation for 1 hour at 4°C. Pre-equilibrated Ni-NTA Superflow resin (Qiagen) was then 
added to the protein cocktail and incubated with gentle agitation for another hour at 4°C. 
Beads were then sedimented by centrifugation at 10,000 × g for 3 min, followed by washing 
thrice with 3T3 lysis buffer. Proteins were then resolved by SDS-PAGE with PKD1 protein 
run alongside as a positive control, following by immunoblotting using an anti-PKD1 
antibody. 
SPOT synthesis of peptides and overlay experiments 
This was done as described by us in detail elsewhere [31]. 
Immunostaining and phalloidin staining of actin 
For immunofluorescent labeling, cardiac myocytes were plated onto laminin-coated 8-well 
chamber slides (Lab-Tek, Sigma). Cells were fixed in 95% ice-cold methanol/ 5% acetone 
mixture at −20°C for 10 min and permeabilised with 0.1% Triton X-100 in PBS for 10 min at 
room temperature. After several washes with Tris-buffered saline (TBS) (150 mM NaCl, 20 
mM Tris–HCl, pH 7.6), the cells were blocked with 10% donkey serum and 2% BSA (w/v) in 
TBS for 2 h followed by three washes with TBS. The primary antibodies used was diluted to 
the required concentration in blocking buffer diluted 1:1 with TBS and added to the cells for 
2 h followed by three washes with TBS. After washing, cells were incubated with 1:400 
diluted secondary antibodies Alexa Fluor 488 donkey anti-mouse IgG and Alexa Fluor 594 
donkey anti-rabbit IgG (Molecular Probes) for 1 h. For phalloidin staining, actin fibers were 
stained with Alexa Fluor 488 phalloidin (Molecular Probes, Invitrogen) diluted 1:500 in PBS 
for 30 min at room temperature and washed thrice in PBS. DAPI (Invitrogen) was used for 
nuclear counterstain. Staining was visualised using a Zeiss Pascal laser-scanning confocal 
microscope (LSM) 510 Meta and an Axiovert 100 microscope (Carl Zeiss, UK) equipped 
with an oil immersion objective (63×/1.4 NA plan apochromat lens). Single-plane images 
were captured at the same depth and processed on Zeiss LSM Image Examiner. For 
quantitative colocalisation analysis, Pearson’s (Rr), Manders’ overlap (R) and colocalisation 
coefficients (M1, M2) were calculated for at least 10 individual cells selected randomly using 
the ImageJ JACoP plugin (http://rsb.info.nih.gov/ij/plugins/track/jacop.html). M1 signifies 
the correlation of Hsp20 overlapping PKD1, while M2 indicates the overlap coefficient of 
PKD1 to HSP20. A background correction was performed prior to analysis to eliminate 
system variability in the image background. 
Real-time xCELLigence measurements 
Cellular size of cardiac mycytes using xCELLigence technology was carried out as described 
previously [15]. An initial population of 40,000 cardiac myocytes/well was plated out on the 
laminin (BD Biosciences) pre-coated E-Plate 96 (Roche) in triplicates after background 
measurements were taken. Briefly after 48 h of culture in the serum-free medium, cardiac 
myocytes were treated with either 10 μM ISO alone or ISO following a 30 min or 2 h pre-
treatment with peptides. Controls with vehicle (DMSO alone) were also performed. The 
cultures were continuously monitored for up to 48 h and the impedance as reflected by cell 
index (CI) values was set to record every 30 min. The xCELLigence data were then analysed 
using the RTCA software (Roche Applied Science). The results were expressed by 
normalized CI, which are derived from the ratio of CIs before and after the addition of 
compounds. 
Measurement of protein content 
Cardiac myocytes were plated on six-well plates and cultured in a serum-free condition for 48 
h before experiments. After stimulation of cardiac myocytes (2 h of compound + 24 h of ISO 
or 24 h of ISO alone), each well was rinsed three times with cold PBS. The cells were then 
scraped with 1 ml of 1× standard sodium citrate (SSC) containing 0.25% (w/v) SDS and 
vortexed extensively. The total cell protein and the DNA content were determined according 
to the manufacturers’ instructions using Total Protein Kit (Sigma #TP0200) and DNA 
Quantitation Kit (Sigma #DNA-QF), respectively. The protein content was normalised by the 
DNA amount to correct for differences in the cell number. 
Quantitative real-time PCR analysis of fetal gene expression 
Total RNA of each condition was extracted using a TRIzol reagent (Invitrogen) and purified 
with the RNeasy Mini Kit (Qiagen). One microgram of DNase-digested total RNA was 
reverse-transcribed to first strand complementary DNA (cDNA) using AffinityScript 
Multiple Temperature cDNA synthesis kit (Agilent, Edinburgh, UK) according to 
manufacturer’s instructions. Real-time PCR primer-probe sets (Eurofins MWG operon) were 
design assisted by the Primer 3 software. Primer-probe sets were as follows: Atrial natriuretic 
peptide (ANP): 5′-AGGCTGCAACAGCTTCCGGT-3′ (probe), 5′-
GGATTGGAGCCCAGAGCGGAC-3′ (sense), 5′-CGCAAGGGCTTGGGATCTTTTGC-3″ 
(antisense); Brain natriuretic peptide (BNF): 5′-GCTGCTGGAGCTGATAAGAGAAAAGT-
3′ (probe), 5′-AGCCAGTCTCCAGAACAATCCACG-3′ (sense), 5′-
AGGGCCTTGGTCCTTTGAGAGC-3′ (antisense); β-myosin heavy chain (β-MHC): 5′- 
CTGGATGAGGCAGAGGAGAG-3′ (probe), 5′-CCAACACCAACCTGTCCAA-3′ (sense), 
5′-CAGCTTGTTGACCTGGGACT-3′ (antisense) and rat 18S rRNA: 5′- 
TGAGGCCATGATTAAGAGGG-3′ (probe), 5′-CGCGGTTCTATTTTGTTGGT-3′ (sense), 
5′-CGGTCCAAGAATTTCACCTC-3′ (antisense). Rat 18S rRNA was used as an internal 
control for normalising relative expression levels in the different samples. Real-time PCR 
reactions were prepared using Platinum® Quantitative PCR SuperMix UDG with ROX 
(Invitrogen) and performed in a 7300 Real time PCR System (Applied Biosystems). Each 
PCR amplification was run in triplicate using the following conditions: 2 min at 95°C, 
followed by a total of 40 cycles (15 s at 95°C and 1 min at 60°C). Relative gene expression 
was calculated using the comparative threshold method (2
-∆∆Ct
) and is presented as fold 
change of transcripts for gene of interest compared to 18 s rRNA. 
Duolink™ proximity ligation assay 
PKD1 association with HSP20 was investigated further by using the Duolink™ Proximity 
Ligation Assay (PLA) (Olink Bioscience, Uppsala, Sweden). After fixation, permeabilisation 
and blocking, slides were incubated with primary antibodies against PKD1 and HSP20 raised 
in two different species. Then PLA probes, which are conjugated with oligonucleotides, were 
introduced to recognise the primary antibodies. A solution that promotes hybridization 
between the PLA oligos was then added, where a hybridisation reaction only occurred if the 
two proteins were in close proximity (<40 nm), but not if they were far apart. This reaction 
was followed by ligation of the oligonucleotides and a rolling circle amplification (RCA) 
reaction, where a repeated sequence product was made. This product was then detected using 
fluorescently labeled oligonucleotides, where a Hsp20-PKD1association appeared as discrete 
red dots under the microscope. Cells were counterstained with α-actinin to show sarcomeric 
stained. Slides were finally mounted under coverslips with DUOLINK mounting media and 
visualised. In order to detect all PLA signals, a series of Z-stack images was collected. 
Subcellular fractionation of cardiac myocytes 
Cardiac myocytes were fractionated into cytosolic, membrane and nuclear fractions using 
FractionPrepTM (BioVision, Mountain View, CA) following the manufacturer’s protocol. 
Equal amounts of each cell lysate were used for Western blot analysis. To assess the purity of 
fractionation, cytoplasmic, membrane and nuclear fractions were confirmed by 
immunoblotting using anti-HSP90 as cytoplasmic marker, anti-GM130 as membrane marker 
and anti-Lamin A/C as nuclear marker, respectively. 
Minimally invasive transverse aortic banding and transthoracic 
echocardiography 
Healthy adult male C57BL/6 J mice (Harlan, UK) weighing between 25-30 g were used for 
these experiments. Procedures conformed to the UK Animals (Scientific Procedures) Act 
1986 and were approved by institutional ethical review committees. MTAB and sham 
surgical protocols were performed as previously described [29]. Immediately following 
surgery, animals were injected (intraperitoneal) with either Hsp20-PKD1disruptor peptide or 
a scrambled control peptide at 10 mg/kg twice weekly and were left for 4 weeks to allow 
cardiac remodeling to occur. Echocardiographic assessment of left ventricular (LV) function 
was performed 4 weeks after MTAB or sham surgery, as described previously [29]. LV end 
systolic dimension (LVESD) and LV end diastolic dimension (LVEDD) were assessed from 
M-mode traces and % fractional shortening calculated. Fractional shortening (FS) is 
expressed as [(LVEDD-LVESD)/LVEDD] ×100. An average of three measurements of each 
variable per animal was used. 
Picrosirius red staining 
Four weeks post-surgery, animals were euthanized with an intravenous injection of 
pentobarbital sodium (Euthatal, 200 mg/kg). Terminal anaesthesia was confirmed by testing 
loss of the pedal reflex. Hearts were rapidly excised and washed thoroughly in ice-cold Ca
2+
-
free Krebs solution (120 mM NaCl, 5.4 mM KCl, 0.52 mM NaH2PO4, 20 mM HEPES, 11.1 
mM glucose, 3.5 mM MgCl2, 20 mM Taurine, 10 mM Creatine; pH 7.4). LV tissue was 
processed, embedded in paraffin and sectioned. Slides were stained for 1 h in picrosirius red 
solution containing 0.1% (w/v) direct red 80 dye in a saturated aqueous solution of 1.3% 
picric acid. Five random sections per heart (5 μm sections with a distance of 200 μm between 
sections), and 5 areas of interest per section were photographed at 10× magnification using 
non-polarised light with a Leica DM LB2 microscope and a Leica DFC 320 camera (Leica 
Microsystems, Germany). Quantification of picrosirius red staining used ImageProPlus 
software (version 5.0; MediaCybernetics), with stained area expressed as a percentage of the 
total area of interest. Values were averaged to give one representative value per heart. For 
calculation of threshold, the intensity of signal for background was set using unstained area 
of tissue. 
Statistical analysis 
Values are presented as mean ± S.E.M. from at least three independent experiments. 
Statistical significances between groups were determined by the use of Student’s t-test or 
one-way ANOVA tests followed by post hoc Tukey’s tests. Values were considered 
significant if p < 0.05. Where representative immunoblots or immunocytochemistry images 
were shown, similar data were obtained n ≥ 3 times. 
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